Combining systemic inflammatory response index and albumin fibrinogen ratio to predict early serious complications and prognosis after resectable gastric cancer

Table 3 Differences in preoperative systemic inflammation response index and albumin fibrinogen ratio at varying levels of clinicopathological variables in gastric cancer patients

Variables		Preoperative SIRI, median (IQR)	1P value	Preoperative AFR, mean ± SD	2P value
Sex	Male	1.11 (0.89)	0.002a	11.96 ± 3.68	0.252
	Female	0.91 (0.87)		11.62 ± 2.77
Age in yr	< 60	1.03 (0.86)	0.038a	12.58 ± 3.83	< 0.001a
	≥ 60	1.14 (0.96)		11.26 ± 3.04
Underlying disease	No	1.07 (0.90)	0.187	11.88 ± 3.55	0.989
	Yes	1.14 (0.91)		11.89 ± 3.31
BMI	< 24	1.06 (0.89)	0.29	11.82 ± 3.60	0.464
	≥ 24	1.15 (0.85)		12.06 ± 3.23
Tumor location	Upper third	1.17 (1.09)	0.164	11.63 ± 3.09	0.695
	Middle third	1.00 (0.80)		12.36 ± 3.14
	Lower third	1.07 (0.88)		11.88 ± 3.61
Tumor dimensions in cm	< 3	0.89 (0.69)	< 0.001a	13.44 ± 3.86	< 0.001a
	≥ 3	1.17 (0.92)		11.26 ± 3.13
Differentiation	Moderate and poor	1.08 (0.90)	0.235	11.80 ± 3.46	0.002
	Well	0.91 (0.71)		14.11 ± 3.90
TNM stage	I	0.78 (0.58)	< 0.001a	13.70 ± 4.20	< 0.001a
	II	1.08 (0.93)		11.66 ± 3.41
	III	1.20 (0.92)		11.24 ± 2.90
Surgical approach	Open	1.16 (0.89)	0.261	12.05 ± 3.97	0.617
	Laparoscopic	1.05 (0.87)		11.90 ± 3.29
	Robot-assisted	1.08 (0.97)		11.68 ± 3.22
Operation	Subtotal gastrectomy	0.97 (0.84)	0.008a	12.10 ± 3.41	0.169
	Total gastrectomy	1.15 (0.94)		11.67 ± 3.58
ASA	I-II	1.07 (0.90)	0.458	11.89 ± 3.53	0.906
	III-IV	1.23 (0.85)		11.83 ± 3.24
Perioperative transfusion	No	1.02 (0.81)	< 0.001a	12.37 ± 3.50	< 0.001a
	Yes	1.44 (1.20)		10.25 ± 3.00
CA199 in ng/mL	Negative	1.06 (0.86)	0.023a	12.14 ± 3.16	0.001a
	Positive	1.23 (1.17)		10.57 ± 2.83
CEA in ng/mL	Negative	1.03 (0.83)	< 0.001a	12.24 ± 3.59	< 0.001a
	Positive	1.29 (1.30)		10.58 ± 2.81
Blood loss in mL	< 200	1.02 (0.77)	0.011a	12.24 ± 3.63	0.013a
	200 ≤ X ≤ 400	1.16 (1.02)		11.49 ± 3.32
	> 400	1.25 (0.95)		11.00 ± 3.00
Relapse or metastasis	No	0.93 (0.82)	< 0.001a	12.65 ± 3.35	< 0.001a
	Yes	1.48 (1.07)		9.40 ± 2.77
P53	Wild	1.14 (0.94)	0.372	11.89 ± 3.40	0.997
	Mutant	1.06 (0.82)		11.89 ± 3.56
Ki-67	0%-49%	0.92 (0.79)	0.183	12.58 ± 3.16	0.249
	50%-74%	1.14 (0.79)		11.87 ± 3.30
	75%-100%	1.07 (0.95)		11.76 ± 3.66
Her-2	Negative	1.08 (0.91)	0.795	11.88 ± 3.53	0.891
	Positive	0.98 (0.75)		11.95 ± 3.19
Lymph node metastasis rate, %	< 4.60%	1.07 (0.90)	0.471	11.95 ± 3.55	0.112
	≥ 4.60%	1.20 (0.83)		11.10 ± 2.81
Enteral nutrition time	≤ 7 d	1.06 (0.91)	0.087	12.18 ± 3.62	0.01a
	> 7 d	1.15 (0.88)		11.40 ± 3.23

^aP < 0.05.

¹P value using Mann-Whitney U test with median (interquartile range).

²P value using Student’s t-test with mean ± standard deviation.

AFR: Albumin fibrinogen ratio; ASA: American Society of Anesthesiology; BMI: Body mass index; CA199: Carbohydrate antigen 199; CEA: Carcinoembryonic antigen; IQR: Interquartile range; SD: Standard deviation; SIRI: Systemic inflammation response index; TNM: Tumor-node-metastasis.